ANRO vs. ERAS, MREO, RANI, TERN, HROW, ADCT, ESPR, AMRN, CRBP, and NATR
Should you be buying Alto Neuroscience stock or one of its competitors? The main competitors of Alto Neuroscience include Erasca (ERAS), Mereo BioPharma Group (MREO), Rani Therapeutics (RANI), Terns Pharmaceuticals (TERN), Harrow (HROW), ADC Therapeutics (ADCT), Esperion Therapeutics (ESPR), Amarin (AMRN), Corbus Pharmaceuticals (CRBP), and Nature's Sunshine Products (NATR). These companies are all part of the "pharmaceutical preparations" industry.
Alto Neuroscience (NYSE:ANRO) and Erasca (NASDAQ:ERAS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, community ranking, institutional ownership, profitability and media sentiment.
In the previous week, Alto Neuroscience had 7 more articles in the media than Erasca. MarketBeat recorded 13 mentions for Alto Neuroscience and 6 mentions for Erasca. Erasca's average media sentiment score of 0.18 beat Alto Neuroscience's score of -0.22 indicating that Erasca is being referred to more favorably in the news media.
67.8% of Erasca shares are held by institutional investors. 29.8% of Erasca shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Alto Neuroscience has higher revenue and earnings than Erasca.
Erasca received 9 more outperform votes than Alto Neuroscience when rated by MarketBeat users. However, 100.00% of users gave Alto Neuroscience an outperform vote while only 61.54% of users gave Erasca an outperform vote.
Alto Neuroscience presently has a consensus target price of $32.33, suggesting a potential upside of 159.29%. Erasca has a consensus target price of $7.83, suggesting a potential upside of 297.63%. Given Erasca's higher possible upside, analysts clearly believe Erasca is more favorable than Alto Neuroscience.
Alto Neuroscience's return on equity of 0.00% beat Erasca's return on equity.
Summary
Alto Neuroscience beats Erasca on 8 of the 13 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding ANRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alto Neuroscience Competitors List
Related Companies and Tools
